New pharmacotherapy options for multiple myeloma

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 2, 2016, Pages 181-192

  Mina, Roberto ^a   Cerrato, Chiara ^a   Bernardini, Annalisa ^a   Aghemo, Elena ^a   Palumbo, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Firstgeneration novel agents; Myeloma; Second generation novel agents; Therapy

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DARATUMUMAB; DEXAMETHASONE; ELOTUZUMAB; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; ISATUXIMAB; IXAZOMIB; LENALIDOMIDE; MELPHALAN; MONOCLONAL ANTIBODY; OPROZOMIB; PANOBINOSTAT; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; THALIDOMIDE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PROTEASOME INHIBITORS;

EID: 84957438965     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1115016     Document Type: Review

References (72)

1. Howlader N, Noone AM, Krapcho M., et al., editors. SEER Cancer Statistics Review. Bethesda (MD): National Cancer Institute; 1975-2012 [based on 2014 Nov SEER data submission, posted to the SEER web site; cited 2015 Apr 10 ]. Available from: http://seer.cancer.gov/csr/1975-2012/
2. Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med. 2011; 364: 1046-1060.
3. Rajkumar SV, Dimopoulos MA, Palumbo A., et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15: e538-e548.
4. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008; 111: 2521-2526.
5. Fayers PM, Palumbo A, Hulin C., et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011; 118: 1239-1247.
6. Palumbo A, Waage A, Hulin C., et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013; 98: 87-94.
7. Rajkumar SV, Jacobus S, Callander NS., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010; 11: 29-37.
8. Benboubker L, Dimopoulos MA, Dispenzieri A., et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014; 371: 906-917.
9. Magarotto V, Bringhen S, Musto P., et al. Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study. Blood. 2014; 124: abstract 2110.
10. Palumbo A, Bringhen S, Kumar SK., et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014; 15: 333-342.
11. Cavo M, Tacchetti P, Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010; 376: 2075-2085.
12. Harousseau JL, Attal M, Avet-Loiseau H., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010; 28: 4621-4629.
13. San Miguel JF, Schlag R, Khuageva NK., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359: 906-917.
14. Palumbo A, Bringhen S, Rossi D., et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010; 28: 5101-5109.
15. Palumbo A, Bringhen S, Larocca A., et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014; 32: 634-640.
16. Mateos MV, Richardson PG, Schlag R., et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010; 28: 2259-2266.
17. Weber DM, Chen C, Niesvizky R., et al. Multiple Myeloma (009) study investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357: 2133-2142.
18. Dimopoulos MA, Spencer A, Attal M., et al. Multiple Myeloma (010) study investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357: 2123-2132.
19. Palumbo A, Cavallo F, Gay F., et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014; 371: 895-905.
20. Palumbo A, Gay F, Spencer A., et al. A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients. Blood. 2013; 122: abstract 763.
21. Attal M, Lauwers-Cances V, Marit G., et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366: 1782-1791.
22. McCarthy PL, Owzar K, Hofmeister CC., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366: 1770-1781.
23. Leleu X, Attal M, Arnulf B., et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood. 2013; 121: 1968-1975.
24. Morgan G, Palumbo A, Dhanasiri S., et al. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. Br J Haematol. 2015; 168 (6): 820-823.
25. Dimopoulos MA, Leleu X, Palumbo A., et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014; 28: 1573-1585.
26. Larocca A, Montefusco V, Bringhen S., et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 2013; 122: 2799-2806.
27. Baz R, Martin TG, Alsina M., et al. Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: results of a Multicenter Randomized Phase II Study. Blood. 2014; 124: abstract 303.
28. Lacy MQ, LaPlant BR, Laumann KM., et al. Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). Blood. 2014; 124: abstract 304.
29. Rosenbaum CA, Kukreti V, Zonder J., et al. Phase 1b/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) with Lenalidomide-Exposed and/or -Refractory but Proteasome Inhibitor (PI)-Naive or -Sensitive Multiple Myeloma: A Multiple Myeloma Research Consortium Multi-Center Study. Blood. 2014; 124: abstract 2109.
30. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002; 7: 9-16.
31. Altun M, Galardy PJ, Shringarpure R., et al. Effects of PS-341 on the activity and composition of protea- somes in multiple myeloma cells. Cancer Res. 2005; 65: 7896-7901.
32. Moreau P, Avet-Loiseau H, Facon T., et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011; 118: 5752-5758.
33. Kumar S, Flinn I, Richardson PG., et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012; 119: 4375-4382.
34. Moreau P, Pylypenko H, Grosicki S., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011; 12: 431-440.
35. Hanada M, Sugawara K, Kaneta K., et al. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot. 1992; 45: 1746-1752.
36. Meng L, Mohan R, Kwok BH., et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci. 1999; 96: 10403-10408.
37. Siegel DS, Martin T, Wang M., et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012; 120: 2817-2825.
38. Lendvai N, Hilden P, Devlin S., et al. A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014; 124: 899-906.
39. Berenson JR, Klein L, Rifkin RM., et al. Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2014; 32: abstract 8594.
40. Stewart AK, Rajkumar SV, Dimopoulos MA., et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372: 142-152.
41. San-Miguel JF, Hungria VT, Yoon SS., et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014; 15: 1195-1206.
42. Lonial S, Vij R, Harousseau JL., et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012; 30: 1953-1959.
43. Dimopoulos MA, Moreau P, Palumbo A., et al. Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): results from the phase III study ENDEAVOR. J Clin Oncol. 2015; 33 (suppl; abstr 8509).
44. Sonneveld P, Asselbergs E, Zweegman S., et al. Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood. 2015; 125: 449-456.
45. Jakubowiak AJ, Dytfeld D, Griffith KA., et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012; 120: 1801-1809.
46. Bringhen S, Petrucci MT, Larocca A., et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014; 124: 63-69.
47. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5: 769-784.
48. San-Miguel JF, Richardson PG, Gunther A., et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013; 31: 3696-3703.
49. Richardson PG, Schlossman RL, Alsina M., et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013; 122: 2331-2337.
50. Schey S, Brown SR, Tillotson AL., et al. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/ refractory myeloma patients: results of the MUK one randomized dose selection trial. Br J Haematol. 2015. DOI: 10.1111/bjh.13435. [Epub ahead of print].
51. Mey U, Brugger W, Bargetzi M., et al. Multicenter phase II trial of Bendamustine, Lenalidomide and Dexamethasone (BRd) as 2nd-line therapy for multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2014; 124: 4779.
52. Hrusovsky I, Heidtmann HH. Combination therapy of bortezomib with bendamustin in elderly patients with advanced multiple myeloma. Clinical observation. Blood (ASH Annual Meeting Abstracts). 2007; 110: 4851.
53. Ofdani M, Corvatta L, Maracci L., et al. Efcacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J. 2013; 3: e162.
54. Ofdani M, Maracci L, Corvatta L., et al. Bendamustine, Bortezomib and Dexamethasone (BVD) in patients with relapse drefractory multiple myeloma (MM): updated results of a multicenter phase II study. Blood (ASH Annual Meeting Abstracts). 2014; 124: 4734.
55. Mateos MV, Oriol A, Rosinol L., et al. Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. Haematologica. 2015;100:1096-1102.
56. Ponisch W, Holzvogt B, Plotze M., et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. J Cancer Res Clin Oncol. 2014; 140: 1947-1956.
57. Kupperman E, Lee EC, Cao Y., et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010; 70: 1970-1980.
58. Kumar SK, Bensinger WI, Zimmerman TM., et al. Weekly dosing of the investigational oral proteasome inhibitor ixazomib, in relapsed/refractory multiple myeloma: results from a phase 1 study. Blood. 2014;124:1047-1055.
59. Richardson PG, Baz R, Wang M., et al. Phase 1 study of twice-weekly dosing of investigational oral proteasome inhibitor ixazomib in patients with relapsed and/or refractory multiple myeloma. Blood. 2014;124:1047-1055.
60. Kumar SK, Roy V, Reeder C., et al. Phase 2 trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib. Blood. 2013; 122: abstract 1944.
61. Kumar SK, Berdeja JG, Niesvizky R., et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014; 15: 1503-1512.
62. Richardson PG, Hofmeister CC, Rosenbaum CA., et al. Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. Blood. 2013; 122: abstract 535.
63. Hari PN, Shain KH, Voorhees PM., et al. Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study. Blood. 2014; 124: abstract 3453.
64. Feling RH, Buchanan GO, Mincer TJ., et al. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl. 2003; 42: 355-357.
65. Chauhan D, Catley L, Li G., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005; 8: 407-419.
66. Kastritis E, Charidimou A, Varkaris A., et al. Targeted therapies in multiple myeloma. Target Oncol. 2009; 4: 23-36.
67. Mentlik James A, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol. 2013; 4: 481.
68. Jakubowiak AJ, Benson DM, Bensinger W., et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012; 30: 1960-1965.
69. Lonial S, Dimopoulos M, Palumbo A., et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373:621-631.
70. Moreau P, Mateos M-V, Bladé J., et al. An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma. Blood. 2014; 124: abstract 176.
71. Pleasner T, Arkenau H-T, Lokhorst HM., et al. Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma. Blood. 2014; 124: abstract 84.
72. Martin TG, Baz R, Benson DM., et al. A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood. 2014; 124: abstract 83.